UTMD technology mediates the application of resveratrol nanocarriers in the diagnosis and treatment of gastric cancer

Gastric cancer remains one of the most prevalent and lethal malignancies worldwide. Resveratrol has demonstrated significant anticancer properties across multiple cancer types, including gastric cancer. However, its therapeutic efficacy is limited by poor bioavailability and rapid metabolic clearance. Recent advances in nanotechnology have enabled the development of innovative drug delivery systems combining ultrasound-targeted microbubble destruction (UTMD) technology with nanocarriers, Exploiting the enhanced permeability and retention (EPR) effect, nanotech-based drug delivery system facilitate enhanced vascular penetration and tumor tissue accumulation, resulting in prolonged systemic circulation, improved therapeutic efficiency, and reduced systemic toxicity. The integration of nanotechnology-based delivery systems with UTMD technology enhances the bioavailability of poorly soluble drugs while providing a safe and targeted approach for resveratrol delivery, thereby optimizing its therapeutic and diagnostic potential in gastric cancer treatment. This review explores the applications of UTMD-mediated resveratrol nanocarriers in the diagnosis and treatment of gastric cancer. • Polygonum cuspidatum links traditional gastric remedies to modern oncology via resveratrol. • Integrates antitumor mechanisms, pharmacokinetics, and safety of resveratrol. • Resveratrol targets gastric cancer through apoptosis, metastasis blockade, and H. pylori inhibition. • Pharmacokinetic challenges and nano-delivery strategies to enhance bioavailability are reviewed.